Autopsy report · NCT04093505

Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Study turned out no longer feasible. End of Recruitment: 25.5.2022”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 years 5 months before it started.
Ran for about 1 year 3 months before it stopped.
28 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: University Hospital Heidelberg
Sponsor type: University, hospital or other
Conditions: Acute Myeloid Leukemia
Interventions: Gemtuzumab Ozogamicin 147; Gemtuzumab Ozogamicin 1; Glasdegib; Placebo Oral Tablet
Participants: 28
Sites: 1
Countries: Germany

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.